Results of ALTA-1 trial: Patients given brigatinib saw a statistically significant 51 percent reduction in the risk of progression or death compared with those given crizotinib.
Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.
Omacetaxine (to block protein synthesis) with venetoclax (to block oxidative phosphorylation), was highly effective against CD123+ leukemia stem cells.
Rattlesnakes and other venomous reptiles may bite more people during rainy years than in seasons wracked by drought, a new study shows.
Increasing natural disasters and aging schools built before modern codes existed put thousands of school-aged children at risk each day. A new guide and webinar series offer solutions.
Best known as a pathogen that causes food poisoning or steals nutrients away from its host, the E. coli bacterium actually plays a critical role in promoting health by producing a compound that helps cells take up iron.
Doctors with personal experience of cancer are more likely to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
A new, super-insulating gel developed by researchers at the University of Colorado Boulder could dramatically increase the energy efficiency of skyscrapers and other buildings, and might one day help scientists to build greenhouse-like habitats for colonists on Mars.
Adolescents with serious conduct and substance use problems are five times more likely to die prematurely than their peers, with roughly one in 20 dying by their 30s, according to new research.
University of Colorado Cancer Center study shows that common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be slipping through the cracks.
Clinical trials at CU Cancer Center and elsewhere result in FDA approval of the drug ivosidenib for the treatment of adult patients with IDH1+ AML.
Scientists have developed a device that uses a small plate to absorb microwave energy and bounce it into laser light—a crucial step for sending quantum signals over long distances.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right